feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Patel Engineering wins ₹798 crore order

trending

Whirlpool shares crash on reports

trending

Mars rover detects electrical sparks

trending

Comet ATLAS explodes into pieces

trending

Sensex, Nifty near record highs

trending

CTET 2026 Registration Begins

trending

RRB NTPC registration closes today

trending

Cyclone Ditwah intensifies over Bengal

trending

Shein faces EU scrutiny

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / FDA Approves Alfapump for Liver Cirrhosis Relief

FDA Approves Alfapump for Liver Cirrhosis Relief

25 Nov

•

Summary

  • First alfapump implantation occurred at Mount Sinai Hospital in the U.S.
  • The device automatically removes ascites fluid for natural elimination.
  • It aims to significantly improve quality of life for patients.
FDA Approves Alfapump for Liver Cirrhosis Relief

A significant advancement in medical technology, the alfapump, has received FDA approval for the treatment of ascites related to liver cirrhosis in the United States. This innovative device was first implanted at Mount Sinai Hospital, marking a new era for patients suffering from this condition.

The alfapump offers a revolutionary approach by automatically removing ascitic fluid from the abdomen. This fluid is then directed to the bladder for natural elimination through urination, effectively ending the need for repeated and invasive drainage procedures. Patients can now anticipate a life free from the burden of frequent interventions.

Dr. Rahul Patel highlighted the alfapump as a transformative technology, emphasizing its potential to enhance patient quality of life and decrease hospitalizations. This breakthrough offers a less invasive and more continuous management of ascites, providing much-needed relief and hope for those affected by this challenging medical condition.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The alfapump is approved by the FDA for the treatment of recurrent or refractory ascites due to liver cirrhosis.
The alfapump automatically removes ascitic fluid from the abdomen into the bladder for natural elimination via urination.
The first alfapump implantation in the U.S. occurred at Mount Sinai Hospital.

Read more news on

Healthside-arrow

You may also like

Boy, 22, Dies at Mental Health Hospital After Morphine Overdose

25 Nov • 6 reads

article image

Man's Stroke Mimics Choking, Defying Age and Odds

22 Nov • 31 reads

article image

Hospital Boosts Efficiency and Patient Safety with Smart Pump-EHR Integration

17 Nov • 43 reads

article image

Newcomers in Hamilton Empowered to Advocate for Their Needs

17 Nov • 39 reads

Cardiologist Shares 10 Proven Tips to Add a Decade to Your Life

16 Nov • 48 reads

article image